Abstract
Feline calicivirus cause feline respiratory diseases, and inactivated and attenuated vaccines are available for its prevention. Moreover, the presence of vaccine breakdown strains (VBS) is problematic. In Japan, feline recombinant interferon (rFeIFN) has been used for its treatment. However the method of compare with each strains has not established. To examine the relationship between the breakdown vaccine strain and rFeIFN sensitivity, the sensitivity of 47 field isolates to rFeIFN was determined. The Log PDD50 values were normally distributed within the range 1.1–3.7, with a mean value of 2.3 ± 0.64. Since 68.3% of the PDD values fell in the range of the mean ± standard deviation, the values in the range 1.7–2.9, the lower values, and the higher values were defined as representing moderate, low, and high sensitivity, respectively. Among the 15 vaccine breakdown strains, strain Fukuoka9 showed a low sensitivity, but strains ML89, T58, and N74 were highly sensitive, showing no association with vaccine breakdown. The amino acid sequence changes specific to the low rFeIFN-sensitive Fukuoka-9 strain were found, suggesting that these sites are involved in rFeIFN sensitivity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Reference
Fulton, R. W. and Bunge, L. J. 1985. Susceptibility of feline herpesvirus 1 and 2 and feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrob. Agents, Chemother. 28: 688–699.
Gaskell, R. M. and Dawson, S. 1998. Feline respiratory disease. In: C.E. Greene (ed.), Infections Diseases of the Dog and Cat, 2nd edn, (WB Saunders, Philadelphia): 97–106.
Isaacs, A. and Lindenmann, J. 1987. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957. J. Interferon. Res. 7: 429–438.
Lindenmann, J. and Gifford, G. E. 1963. Studies on vaccinia virus plaque formation and its inhibition by interferon. III. A simplified plaque inhibition assay of interferon. Virology. 19: 302–309.
Mochizuki, M., Nakatani, H., Yoshida, M. 1994. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet. Microbiol. 39: 145–152.
Mochizuki, M., Kawakami, K., Hashimoto, M., Ishida, T. 2000. Recent epidemiological status of feline upper respiratory infections in Japan. J. Vet. Med. Sci. 62: 801–803.
Nagano, Y. and Kojima, Y. 1954. Pouvoir immuninant da virus vaccinal inactive par des rayons ultaviolets. C.R. Soci. Biol. 1700–1708.
Ninomiya, H., Fukutome, A., Kashima, M., Kobayashi, K., Shin, Y., Uchino, T., Motoyoshi, S. 1991. Effects of recombinant feline interferon on feline calicivirus infection. Proceeding of the12th annual meeting of Japanese society of clinical veterinary medicine. 384–387. (In Japanese)
Ohe K., Sakai S., Takahashi T., Sunaga F., Murakami M., Kiuchi A., Fukuyama M., Furuhata K., Hara M., Ishikawa Y., Taneno A. 2007 Genogrouping of vaccine breakdown strains (VBS) of feline calicivirus in Japan, Vet.Res.Commun. 31: 497–507
Orito, E., Mizokami, M., Mizoguchi, N., Ohba, K., Tohnai, M., Yamanaka, H., Oguri, T., Hirashima, N., Koide, T., Kano, H. 1994. Hepatitis C virus serotype II responds more favorably to interferon-alpha therapy. J. Hepatol. 21: 130–132.
Pedersen, N. C. 1993. Feline infectious diseases. (American Veterinary Publications, California, USA): 58–64.
Sato, Y., Ohe, K., Fukuyama, M., Furuhata, K., Kishikawa, S., Suzuki, Y., Kiuchi, A., Hara, M., Ishikawa, Y., Taneno, A. 2002a. Phylogenetic analysis of feline calicivirus capsid gene in infected cats. Jpn. J. Electroph. 46: 7–14.
Sato, Y., Ohe, K., Murakami, M., Fukuyama, M., Furuhata, K., Kishikawa, S., Suzuki, Y., Kiuchi, A., Hara, M., Ishikawa, Y., Taneno, A. 2002b. Phylogenetic analysis of field isolates of feline calicivirus (FCV) in Japan by sequencing part of its capsid gene. Vet. Res. Commun. 26: 205–219.
Uchino, T., Kouzuki, S., Yamane, Y., Motoyashi, S. 1991. Clinical effect of recombinant feline interferon (rFeIFN) on feline calicivirus infection (FCI). Proceeding of the12th annual meeting of Japanese society of clinical veterinary medicine. 388–395. (In Japanese)
Uchino, T., Kouzuki, S., Tsuruno, M., Yamane, Y., Uno, T., Kumai, H., Kobayashi, K., Kobayashi, K., Skurai, F., Sasaki, T., Shimoda, K., Shimoda, T., Kawamura, H., Tajima, T., Mochizuki, M., Motoyashi, S. 1992. Investigations of feline interferon and its therapeutic effects for field use (Report 1) Its therapeutic effects on FCI (feline calicivirus infection), Japanese Journal of Small Animal Practice. 11: 11–25. (In Japanese)
Uchino, T., Yamane, Y., Motoyashi, S. 1998. Research of 245 cases of field trial on clinical effect of recombinant feline interferon-ω (omega) on feline calicivirus infection (FCI). Proceedings of the 19th annual meeting of Japanese society of clinical veterinary medicine. 3: 58–76. (In Japanese)
Ueda, Y., Sakurai, T., Kasama, K., Satoh, Y., Atsumi, K., Hanawa, S., Uchino, T., Yanai, A. 1993. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′, 5′-oligoadenylate synthetase activity in the cat. J. Vet. Med. Sci. 55: 1–6.
Wagner, R. R. 1961. Biological studies of interferon. I. Suppression of cellular infection with eastern equine encephalomyelitis virus. Virology. 13: 323–337.
Yamamoto, K. J., Okuda, T., Yanai, K. 1990. Feline interferon no kenkyuu. II. Feline interferon no FHV hassyouyokuseikouka. Proceeding of 109th The Japanese Society of Veterinary Science. 153.
Yanai, K., Nakamura, N., Sudou, T. 1990. Feline interferon no kenkyuu. I. Feline interferon cDNA no cloning. Proceeding of 109th The Japanese Society of Veterinary Science. 153.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohe, K., Takahashi, T., Hara, D. et al. Sensitivity of FCV to recombinant feline interferon (rFeIFN). Vet Res Commun 32, 167–174 (2008). https://doi.org/10.1007/s11259-007-9019-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11259-007-9019-5